Our Services
Medical Information
Helpful Resources
Published on: 9/17/2026
Semaglutide (Ozempic, Wegovy) has been linked to rare but serious acute pancreatitis and to a higher risk of gallstones and gallbladder inflammation, particularly with rapid weight loss, higher doses, or a prior history of these conditions. Red flag symptoms include severe upper abdominal pain that may spread to the back, persistent nausea or vomiting, fever, or yellowing of the eyes and skin, all of which need prompt medical evaluation. Because risk depends on your dose, how quickly you are losing weight, alcohol use, gallstone history, and other medications, there are several important factors to consider before assuming your symptoms are ordinary side effects, and those details are explained below.
If your stomach pain, nausea, or digestive changes started after beginning semaglutide, it is worth clarifying quickly whether this looks like a common adjustment effect or something that requires urgent care, since pancreatitis and gallbladder attacks worsen fast when ignored. Take a free, instant, online symptom check to sort your symptoms by likely cause, see which warning signs apply to you, and get clear guidance on whether to call your prescriber, seek same-day care, or continue monitoring at home.
Last reviewed for medical accuracy: 09/17/2026
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for type 2 diabetes and chronic weight management. As its use grows, patients and clinicians often wonder about rare but serious side effects—specifically pancreatitis and gallbladder issues.
Semaglutide (brand names Ozempic®, Rybelsus®, Wegovy®) mimics the hormone GLP-1 to:
These effects help control blood glucose and reduce appetite, often leading to significant weight loss.
Pancreatitis is inflammation of the pancreas, a potentially serious condition. Early concerns linked GLP-1 agonists to pancreatitis based on animal studies and post-marketing reports. Here’s what large human studies and regulatory agencies say:
If you take semaglutide, monitor for warning signs:
What to do:
If you experience these symptoms, stop semaglutide and seek medical attention immediately. You can also try a free, online symptom check, using the doctor approved Ubie Symptom Checker to help clarify next steps.
Rapid weight loss—even when healthy—is a known risk factor for gallstone formation. Semaglutide users often lose 5–15% of body weight, which can:
Watch for:
What to do:
Discuss any alarming symptoms with your healthcare provider. A timely ultrasound can detect gallstones or gallbladder inflammation.
While rare, pancreatitis and gallbladder issues deserve attention. Here’s how you and your doctor can minimize risk:
Always consult your healthcare provider if you experience:
These signs could indicate life-threatening conditions. Prompt medical evaluation is essential.
If you have concerns about semaglutide’s side effects or experience worrisome symptoms, speak to a doctor right away. For additional peace of mind, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
(References)
* Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14. PMID: 31422062.
* Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. doi: 10.3389/fendo.2021.645563. Epub 2021 Jul 7. PMID: 34305810; PMCID: PMC8294388.
* Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S, STEP TEENS Investigators. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022 Dec 15;387(24):2245-2257. doi: 10.1056/NEJMoa2208601. Epub 2022 Nov 2. PMID: 36322838; PMCID: PMC9997064.
* Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605/jafes.037.02.14. Epub 2022 Aug 23. PMID: 36578889; PMCID: PMC9758543.
* Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. doi: 10.3389/fendo.2023.1214334. Epub 2023 Oct 16. PMID: 37908750; PMCID: PMC10613702.
* Long B, Pelletier J, Koyfman A, Bridwell RE. GLP-1 agonists: A review for emergency clinicians. Am J Emerg Med. 2024 Apr;78:89-94. doi: 10.1016/j.ajem.2024.01.010. Epub 2024 Jan 12. PMID: 38241775.
* Masson W, Lobo M, Barbagelata L, Lavalle-Cobo A, Nogueira JP. Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis. Endocrinol Diabetes Nutr (Engl Ed). 2024 Mar;71(3):124-132. doi: 10.1016/j.endien.2024.03.012. PMID: 38555109.
* Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024 Dec;12:100127. doi: 10.1016/j.obpill.2024.100127. Epub 2024 Aug 31. PMID: 39286601; PMCID: PMC11404059.
* Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. PMID: 40196933; PMCID: PMC12000858.
* Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026 May 1;83(5):1326-1340. doi: 10.1097/HEP.0000000000001608. Epub 2025 Nov 7. PMID: 41201884.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.